Please login to the form below

Not currently logged in

People, January, 2012

Recent high-profile moves in the pharmaceutical and healthcare industriesMover of the month is Ian Read, who has been elected chairman of the company’s board of directors at Pfizer.

Mover of the month

 Ian Read - Pfizer, CEO Chair

President and CEO of Pfizer, Ian Read, has been elected chairman of the company's board of directors. He succeeds George Lorch, who becomes lead independent director at the company. Lorch commended Read's work since he became CEO of Pfizer in December 2010 following the departure of Jeff Kindler. The company has also made two new scientific appointments to its board of directors. Dr Marc Tessier-Lavigne, president of The Rockefeller University, and Dr Helen Hobbs, professor of internal medicine and molecular genetics at the University of Texas, will both provide their expertise and counsel to Pfizer. Dr Tessier-Lavigne is former executive vice president, research, and chief scientific officer at Genentech and has served on the faculties of several universities. Dr Hobbs is a researcher at the Howard Hughes Medical Institute and director of the McDermott Center for Human Growth and Development at the university of Texas.


A further Lilly appointment is Richard Ascroft as senior director, corporate affairs, for the Australia, Canada and Europe (ACE) region. Formerly head of the company's UK corporate affairs, Ascroft will lead regional government affairs, communications, public policy, advocacy and professional relations, and corporate social responsibility. He has been at Lilly since 1993, with his roles including five years as director of corporate affairs for Lilly's emerging markets and Japan businesses from 2004 to 2009. Taking over Ascroft's former UK role is Thom Thorp. Previously, he led government and external affairs activity in the UK and most recently he was regional access manager, diabetes south, in the UK.




Roche's Dr Hagen Pfundner has been elected chairman of the German pharmaceutical industry association, the Verband Forschender Arzneimittelhersteller (VFA). He succeeds Bayer's Dr Wolfgang Plischke and will serve alongside Dr Andreas Penk from Pfizer, who is confirmed as deputy chairman. Dr Pfundner is the CEO of Roche Pharma AG, Germany and managing director of Roche Holding GmbH Germany. One of Dr Pfundner's first tasks at the VFA will be to push for further changes to the reforms outlined for AMNOG, Germany's system for pharmaceutical pricing and reimbursement.

Merck Sharp & Dohme's (MSD) UK managing director Deepak Khanna is to take over as president of the Association of the British Pharmaceutical Industry (ABPI) in April 2012. Khanna will succeed GlaxoSmithKline's UK general manager Simon Jose when his one-year term ends. Holding both US and UK citizenship, Khanna has worked on both sides of the Atlantic for MSD in Europe and its parent company Merck & Co in the US. He managed all aspects of the US Merck/Schering-Plough Joint Venture and was responsible for leading the US integration planning efforts between the two companies after they agreed to merge in 2009. Khanna has already worked closely with the ABPI, serving as a member of the body's Board of Management, chair of its Health Technology Assessment Taskforce and chair of the American Pharmaceutical Group.



Merck & Co has promoted its former global head of infectious diseases Roger Pomerantz to a new role as the US company's head of worldwide licensing and knowledge management. He will lead all licensing deals, acquisitions, academic alliances, regional deals and out-licensing, as well as playing a key part in the Merck Research Venture Fund. Prior to joining Merck in February 2010, he was global head of infectious diseases and president of Peninsula Pharmaceuticals, a subsidiary of Johnson & Johnson (J&J) focused on antibacterial research. From 2005-2010, he also served as president of Tibotec Pharmaceuticals, another J&J subsidiary involved in antiviral and tuberculosis research and development. Before J&J, Pomerantz spent 15 years in academic medicine at Thomas Jefferson University and Medical School in Philadelphia as professor of Medicine, Biochemistry and Molecular Pharmacology, chief of Infectious Diseases and founding director and chair of the Institute for Research in Human Virology and Biodefence.

Roche has promoted Sophie Kornowski-Bonnet from general manager of Roche Pharma in France to head of partnering. She takes up the role on February 1, relocating to the company's headquarters in Basel, Switzerland. Kornowski-Bonnet replaces Dan Zabrowski, who takes over as head of Roche applied science in its diagnostics division in Penzberg, Germany. In her new position, Kornowski-Bonnet will focus on developing strategic alliances and partnerships in R&D. She also joins Roche's corporate executive committee, reporting to Severin Schwan, CEO of the Roche Group. She previously worked at both Abbott Diagnostics and Abbott Pharmaceuticals in regulation, research and sales roles. She led Sanofi's neurology and psychiatry unit in France before joining MSD, where she established a subsidiary in Israel before leading the company's global marketing in osteoarthritis and pain. Zabrowski joined Syntex in 1993, before Roche acquired the company in 1994. He has been with Roche ever since, holding several management positions in pharma development.





US-based Vertex has appointed Jeffrey Leiden as president and CEO. He will take over from Matthew Emmens, who will serve as executive chairman until May and then remain at the company as a director. Dr Leiden has been a director on Vertex's Board since mid-2009 and brings more than 20 years of scientific, commercial and financial experience in the pharmaceutical and biotechnology industries. He will formally take on the role of CEO on February 1. He is a managing director at life sciences venture capital firm Clarus Ventures, which he joined in 2006. Prior to that, he spent six years at Abbott Laboratories as president and chief operating officer. As part of his move to Vertex Dr Leiden will relinquish his board responsibilities at Dublin-based speciality biopharmaceutical company Shire. He currently chairs the company's science and technology committee and is a member of the company's remuneration and nomination committees.

AstraZeneca (AZ) has promoted Lisa Anson to country president of its UK marketing company. She takes charge of AZ's entire UK sales force as well as a sales and marketing team based in Luton and a clinical research group in Edinburgh. The position is not Anson's first role with AZ's UK marketing company, as she previously worked as both head of primary care and head of speciality care. Anson was also vice president of emerging brands in the company's global marketing and sales operations and has also held a number of senior global brand roles. She takes over from Mark Jones, who has been appointed AZ's area vice president for Southern Europe and Israel.


Current president and chief operating officer of Amgen Robert Bradway will take over as CEO of the company in May 2012 following Kevin Sharer's retirement. Sharer will remain as chair of the board of directors until December 2012, after which the company intends to elect Bradway to that position as well. Amgen also announced the retirement of Roger Perlmutter from his position as executive vice president of R&D. He will be replaced by Sean Harper in February, 2012, who currently holds the positions of senior vice president, global development and chief medical officer. Sharer has been CEO of the US pharma company since 2000, while Bradway, has been at Amgen since 2006, initially serving as vice president in operations before becoming chief financial officer in 2007. He has been president and chief operating officer since 2010. Previously, Bradway spent 19 years with Morgan Stanley, including working as MD for the company's London business. Perlmutter has been at Amgen since 2000. Prior to joining Amgen in 2002, Harper worked at Merck Research Laboratories.

Eli Lilly & Co has named former health policy adviser to the US government, Dr Katherine Baicker as a member of its board of directors. She will serve on the public policy and compliance committee for the company. Between 2005 and 2007, she was a member of the President's Council of Economic Advisers. She is research associate at the National Bureau of Economic Research and an elected member of the Institute of Medicine. She also serves on the editorial boards of Health Affairs, the Journal of Health Economics, and the Forum for Health Economics and Policy.

Jeremy Levin will leave Bristol-Myers Squibb (BMS) to take over as president and chief executive of Israel-headquartered Teva Pharmaceutical in May, following the departure of current CEO Shlomo Yanai. Levin is currently senior vice president of strategy at BMS and will take the helm at Teva once 59-year-old Yanai retires after five years in the job. Levin has been with BMS since 2007 and formerly held senior positions at Novartis and Cadus Pharmaceuticals. He will be the first non-Israeli CEO at Teva.

Merck KGaA has promoted its current head of global strategic planning oncology, Isabel De Paoli, to lead the company's global corporate strategy. She reports to Karl-Ludwig Kley, chairman of the German company's executive board. She originally joined Merck in 2006 as part of the chemical business development team and prior to that was a consultant at the Boston Consulting Group. The company has also promoted Dr Friederike Rotsch to head of corporate auditing. Rotsch joined the company in 2005 in the legal department and has been head of corporate legal services.

Affiris has appointed Ali Alloueche to fill the new position of chief business officer. The Austrian biopharmaceutical company said the creation of the role was driven by its expanding pipeline of potential new vaccines for neurological disorders such as Alzheimer's disease. Alloueche has several years of experience working in vaccine development for major pharmaceutical companies. Most recently, he was head of external R&D at GSK Biologicals in Belgium. While working for GSK he identified in-licensing opportunities for Alzheimer´s disease vaccine candidates produced by Affiris that resulted in a €430m deal for the Austrian company. He has also worked as research director at Novartis Vaccines and Diagnostics in Italy and was head of translational medicine and scientific affairs. Alloueche will oversee Affiris' business activities, strategic alliances and partnerships.

Photocure ASA has appointed Torbjørn Øye as its interim chief financial officer. He replaces Christian Fekete who resigned in November after seven years at the Norwegian biotech. Øye joins from management consulting firm Uniconsult AS, and has experience working in financial and accounting departments across a range of industries. Photocure focuses on photodynamic technologies in dermatology and cancer.

Related links

FAQ: How do I get my move listed


Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Why precision medicine demands precision engagement
The speed of innovation brings its own challenges, says cloud computing expert...
Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...